期刊
CANCERS
卷 10, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/cancers10120506
关键词
BRCA; DNA-damaging agents; platinum; poly(ADP)-ribose polymerase
类别
资金
- SIRIC grant INCa-Inserm-DGOS 1068
- La Ligure contre le Cancer (label EL2016.LNCC/DaB)
- Fondation Ruban Rose
- Institut Paoli-Calmettes
Breast cancers (BC) associated with germline mutations of BRCA1/2 represent 3-5% of cases. BRCA1/2-associated BC have biological features leading to genomic instability and potential sensitivity to DNA damaging agents, including poly(ADP-ribose) polymerase (PARP) and platinum agents. In this review, we will summarize clinical trials of chemotherapy and PARP inhibitors (PARPi), alone or in combination, at the early or late stage of BRCA1/2-associated BC. We will also present the mechanisms of resistance to PARPi as well as the new therapeutic strategies of association with PARPi. Finally, we will discuss under which conditions the use of DNA damaging agents can be extended to the BRCA1/2-wild type population, the BRCAness concept.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据